Axsome Therapeutics Inc (NASDAQ:AXSM) CFO Nick Pizzie acquired 1,920 shares of the stock in a transaction dated Tuesday, June 11th. The shares were purchased at an average price of $20.80 per share, for a total transaction of $39,936.00. Following the completion of the purchase, the chief financial officer now directly owns 1,920 shares in the company, valued at $39,936. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Nick Pizzie also recently made the following trade(s):
- On Tuesday, March 19th, Nick Pizzie acquired 5,400 shares of Axsome Therapeutics stock. The stock was acquired at an average cost of $12.58 per share, with a total value of $67,932.00.
Shares of Axsome Therapeutics stock opened at $20.85 on Wednesday. Axsome Therapeutics Inc has a 12 month low of $1.94 and a 12 month high of $26.45. The firm has a market cap of $733.72 million, a PE ratio of -18.13 and a beta of 2.75. The company has a debt-to-equity ratio of 1.08, a quick ratio of 5.68 and a current ratio of 5.68.
Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.01). Sell-side analysts predict that Axsome Therapeutics Inc will post -1.29 earnings per share for the current year.
Several equities analysts recently commented on the stock. Zacks Investment Research raised shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 22nd. BidaskClub lowered shares of Axsome Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday. Finally, Leerink Swann assumed coverage on shares of Axsome Therapeutics in a research report on Monday, April 8th. They set an “outperform” rating and a $25.00 price target on the stock. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $30.83.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Ladenburg Thalmann Financial Services Inc. boosted its holdings in Axsome Therapeutics by 113.7% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,400 shares of the company’s stock valued at $48,000 after acquiring an additional 1,809 shares during the period. Focused Wealth Management Inc bought a new stake in Axsome Therapeutics in the 1st quarter valued at about $64,000. Northern Trust Corp lifted its holdings in shares of Axsome Therapeutics by 15.9% during the 1st quarter. Northern Trust Corp now owns 35,358 shares of the company’s stock worth $503,000 after acquiring an additional 4,843 shares during the period. BlackRock Inc. increased its position in shares of Axsome Therapeutics by 14.6% during the fourth quarter. BlackRock Inc. now owns 64,049 shares of the company’s stock worth $181,000 after buying an additional 8,137 shares during the period. Finally, Barclays PLC bought a new position in Axsome Therapeutics during the fourth quarter worth $30,000. Institutional investors own 44.22% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Nick Pizzie Acquires 1,920 Shares of Axsome Therapeutics Inc (NASDAQ:AXSM) Stock” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.thelincolnianonline.com/2019/06/12/nick-pizzie-acquires-1920-shares-of-axsome-therapeutics-inc-nasdaqaxsm-stock.html.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.
Featured Story: Earnings Reports
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.